Covered recipient · General Payments record
AMINDER MEHDI
General Payments · PY2018–2024
$9,336.53
- Reported across 391 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,216.35 | 53 |
| Long term medical supply or device loan | $199.40 | 2 |
| Education | $79.16 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $271.61 | 7 |
| Janssen Biotech, Inc. | $206.19 | 8 |
| BeiGene USA, Inc. | $107.34 | 5 |
| Lilly USA, LLC | $79.16 | 1 |
| SpringWorks Therapeutics, Inc. | $63.28 | 2 |
| Acerta Pharma LLC | $57.38 | 3 |
| Incyte Corporation | $53.68 | 2 |
| Regeneron Healthcare Solutions, Inc. | $52.19 | 2 |
| E.R. Squibb & Sons, L.L.C. | $50.22 | 2 |
| PFIZER INC. | $48.86 | 2 |
| Genmab U.S., Inc. | $48.58 | 2 |
| ABBVIE INC. | $39.95 | 2 |
| Azurity Pharmaceuticals, Inc. | $36.88 | 2 |
| GlaxoSmithKline, LLC. | $32.44 | 1 |
| Myriad Genetic Laboratories, Inc. | $31.22 | 2 |
| TAIHO ONCOLOGY, INC. | $31.01 | 1 |
| Rigel Pharmaceuticals, Inc. | $29.50 | 1 |
| Genentech USA, Inc. | $27.92 | 1 |
| Gilead Sciences, Inc. | $26.99 | 1 |
| Telix Pharmaceuticals | $26.92 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $25.25 | 1 |
| Celgene Corporation | $24.80 | 1 |
| ADC Therapeutics America, Inc. | $24.07 | 1 |
| Invivyd Inc | $22.77 | 1 |
| SERVIER PHARMACEUTICALS LLC | $22.59 | 1 |
| Merck Sharp & Dohme Corporation | $20.83 | 1 |
| Fennec Pharmaceuticals, Inc. | $19.46 | 1 |
| Amgen Inc. | $13.82 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (56)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.